LINDSEY HOPPEL: Open Payments
NPI 1730601709 · LISBON, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$958 in 55 payments from 10 companies in 2025. Trend: 2023 $331 · 2024 $290 · 2025 $958
Food & beverage: $958
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $393 |
| ABBVIE INC. | 23 | $270 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Indivior Inc. | 1 | $27 |
| Abbott Laboratories | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Lilly USA, LLC | 1 | $15 |
| Corium, LLC | 1 | $14 |
Products named: VRAYLAR, FANAPT, HETLIOZ, REXULTI, CAPLYTA, Auvelity, SUBLOCADE, ABILIFY ASIMTUFII.
Industry payments across OH — which companies pay providers there.
